RRX-001
RRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity; targets CD133 + /CD44 + cancer stem cells from colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc; inhibits HCT 116 and decreases levels of the DNA methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner; RRX-001 (RRX001) is a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia.Lung Cancer Phase 2 Clinical.
Product Specifications
CAS Number
925206-65-1
Product Name Alternative
RRX001 | RRX 001
Purity
>98% (HPLC)
Solubility
DMSO : ≥ 100 mg/mL 373.11 mM
Smiles
O=[N+] (C1 ([N+] ([O-]) =O) CN (C (CBr) =O) C1) [O-]
Molecular Formula
C5H6BrN3O5
Molecular Weight
268.023
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2-bromo-1- (3,3-dinitroazetidin-1-yl) ethan-1-one
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human PCDHGA12 shRNA (UAS) - Lentiviral human PCDHGA12 shRNA (UAS) (25)
Lentiviral mouse Rs1 shRNA (UAS) - Lentiviral mouse Rs1 shRNA (UAS, iRFP) (100)